Shorter Radiation Therapy Schedules: A Practical Solution for Cancer Treatment in Resource-Limited Countries

Table of Contents

• Key Points
• Background: The Global Cancer Challenge
• What Is Hypofractionated Radiotherapy?
• Infrastructure Requirements for Safe Implementation
• Evidence for Breast Cancer Treatment
• Evidence for Prostate Cancer Treatment
• Evidence for Lung Cancer Treatment
• Current Guidelines and Recommendations
• Clinical Implications for Patients
• Limitations and Considerations
• Practical Recommendations
• Frequently Asked Questions
• Source Information

Key Points

• Hypofractionated radiotherapy delivers higher doses per session, shortening breast treatment from 5–6 weeks to 3 weeks or even 1 week.
• Randomised trials show hypofractionation gives cancer control and survival at least as good as conventional radiotherapy for breast, prostate and lung cancers.
• Safe delivery requires a linear accelerator, CT simulation, planning software, immobilisation, quality assurance and trained staff.
• Ultra-hypofractionation has less long-term follow-up data than moderate hypofractionation, so it is often restricted to trials or registered cohorts.
• Shorter schedules reduce travel and accommodation costs and allow each radiotherapy machine to treat more patients.

Background: The Global Cancer Challenge

Cancer creates a massive burden on global health. In 2020, approximately 20 million new cancer cases and 10 million cancer deaths occurred worldwide. Over the next two decades, researchers project that this burden will increase significantly, placing additional strain on healthcare systems, individuals, and communities.

Low- and middle-income countries (LMICs) already account for approximately 60% of cancer cases and the majority of cancer deaths. However, while 88% of high-income countries have access to cancer registries, only 45% of LMICs have such registries. This gap makes it harder to assess local cancer patterns, evaluate demand, plan appropriately, build capacity, and provide access to curative cancer treatment.

Radiotherapy (RT) is a major component of cancer treatment. Almost 50% of patients with cancer will need RT at some point during their treatment. However, only 62% of countries report having readily accessible RT services. The current global shortage of RT infrastructure and investment hinders the achievement of accessible, timely, and high-quality RT.

The disparity in RT access is stark. According to the International Atomic Energy Agency Directory of RT Centers database, high-income countries have one RT machine per 120,000 people. Middle-income countries have one machine for over 1 million people. In low-income countries, a single machine serves approximately 5 million people. LMICs would need to increase RT availability by at least tenfold to approach the same level of access as high-income countries.

This shortage, combined with the rising burden of cancer, requires urgent attention. Hypofractionated radiotherapy has emerged as a viable solution for tackling the scarcity of RT, particularly in LMICs.

What Is Hypofractionated Radiotherapy?

Hypofractionated radiotherapy (HRT) involves administering a higher radiation dose with each session (called a fraction). HRT uses either moderate hypofractionation (more than 2 to 4 Gray per fraction) or ultra-hypofractionation (more than 5 Gray per fraction). This approach reduces the overall duration of RT.

From a radiobiological standpoint, hypofractionation offers many therapeutic benefits, especially for tumors characterized by low alpha/beta ratios. In such cases, larger fractions can deliver a proportionally higher dose to the tumor compared to conventional fractionation (1.8 to 2 Gray per fraction).

The ESTRO-GIRO survey indicates a strong preference for hypofractionation in treating bone metastasis, with more than 85% of respondents choosing this approach. It is also preferred for node-negative breast cancer after lumpectomy (82.2% utilization). However, it is less commonly used for node-positive breast cancer (46.7%, p<0.001). Similarly, hypofractionation is more frequently utilized for low- and intermediate-risk prostate cancer (57.5% and 54.5%, respectively), compared to high-risk prostate cancer (41.2%, p<0.001).

This review systematically evaluates the clinical evidence supporting the use of hypofractionation and ultra-hypofractionation in treating prostate, breast, and lung cancers. It is designed to function as an educational resource, guiding physicians in the effective application of these techniques. This is particularly crucial for LMICs, where resource limitations pose unique challenges.

Infrastructure Requirements for Safe Implementation

Using HRT requires advanced technology, meticulous treatment planning, precise delivery, and stringent quality assurance. These requirements exist because HRT delivers an increased dose per fraction to the target volume.

A notable disparity in the adoption of HRT, particularly in LMICs, can be attributed to substantial gaps in technology and infrastructure. Although not mandatory, certain prerequisites are recommended for safely implementing HRT.

The minimum requirements include:

• A linear accelerator (LINAC) for three-dimensional conformal radiation therapy (3DCRT)
• CT treatment simulation with sub-3mm slice reconstruction
• Both forward and inverse treatment planning software
• Proper immobilization devices
• A comprehensive quality assurance (QA) protocol
• A team of well-trained radiation oncology professionals

These are the minimum standards for safely and adequately delivering HRT. The preferred treatment delivery method involves volumetric modulated arc therapy (VMAT) or intensity-modulated RT (IMRT) using a minimum 6 MV beam. These advanced techniques should be accompanied by onboard image guidance and motion tracking systems.

Regardless of the chosen technique (3DCRT, IMRT, or VMAT), certain QA tasks should be performed more frequently than the standard LINAC QA guidelines of the Task Group 142 report.

In certain clinical cases, safe treatment can be administered to patients without advanced techniques, thanks to the surrounding normal tissue. Modern guidelines typically advocate for at least 3D treatment for enhanced safety and better protection of normal tissue. However, the absence of technology should not be a barrier to adopting HRT, as long as the existing technology ensures safe treatment delivery.

A phase II clinical trial conducted in India used a two-week hypofractionation regimen for patients diagnosed with breast cancer. The trial used a two-dimensional conformal radiation therapy (2DCRT) treatment technique. The study demonstrated favorable outcomes, with acceptable late toxicities, commendable cosmetic results, and excellent local control.

However, for prostate and lung cases, the recommendation is to utilize a minimum of 3D technology. This recommendation emphasizes concerns related to associated toxicity.

The high-dose requirements of HRT and SBRT necessitate strict safety measures for organs at risk (OAR). These measures call for precise margins around the target and advanced image guidance strategies beyond conventional radiographic methods. This demands substantial resources including specialized personnel, technology, and time.

It is crucial to establish clear guidelines, ensure staff certification, provide ongoing training, and implement comprehensive quality management and QA procedures at multiple intervals. These steps secure safe and effective treatment delivery. For details of safe implementation, it is advisable to consult the ASTRO Safety White Paper Update.

Accurate patient positioning and image quality in treatments like SBRT necessitate the use of appropriate localization tools (such as cone beam CT or other 3D imaging methods). Rigorous, ongoing QA procedures are also required, overseen by a qualified physicist during every treatment session. Daily validations of the image-to-accelerator alignment and regular end-to-end tests for new imaging technologies are crucial. Strict adherence to the guidelines outlined in the American Association of Physicists in Medicine Task Group Report 101 is imperative to ensure the safety and effectiveness of the treatment. These recommendations can also be applied to HRT to accommodate the increased dose rate.

Evidence for Breast Cancer Treatment

Breast cancer is the most common malignancy globally. In 2020, breast cancer diagnoses reached 2.3 million women, resulting in 685,000 deaths worldwide. GLOBOCAN's predictions show a concerning increase in breast cancer. By 2040, cases are expected to rise by more than 45%, leading to around 3 million new cases each year. Breast cancer-related deaths are anticipated to go up by more than 50%, from 685,000 in 2020 to 1 million in 2040.

Following surgical interventions like mastectomy or lumpectomy, postoperative radiotherapy is vital in the comprehensive care of breast cancer patients. Postoperative RT significantly lowers the risks of recurrence and breast cancer-related deaths. Implementing HRT for breast cancer in LMICs has the potential to optimize resource utilization and possesses a well-established radiobiological advantage.

Studies suggest that increasing the daily fraction size while reducing the total dose might offer equal tumor control to conventional fractionation (CF), with a theoretical small trade-off of late toxicity. As a result, HRT has been widely embraced, promising better outcomes for patients with breast cancer around the world.

Moderate Hypofractionation for Breast Cancer

Moderate HRT to the breast yields local control and survival outcomes that are at least as effective as those achieved with CF. It has become the standard regimen for whole-breast irradiation (WBI) after breast-conserving surgery or mastectomy in the vast majority of women.

Previously published meta-analyses have thoroughly analyzed various aspects of its effectiveness. Ten-year outcomes were reported in four identified trials: the UK's START trials (P, A, and B), along with the Ontario Clinical Oncology Group (OCOG) trial from Canada.

The START-P and START-A trials were three-arm trials that examined two experimental HRT schedules over 5 weeks. Both START-B and the OCOG trials were pragmatic trials that tested 15 or 16 daily fractions of 2.7 Gray over 3 weeks. These were compared with the historical standard of 50 Gray in 25 fractions daily over 5 weeks.

The OCOG trial included 1,234 women with T1-2N0M0 breast cancer who had undergone breast-conserving surgery followed by CF-WBI or HRT-WBI. The 10-year results showed that HRT-WBI was not inferior, with no discernible differences in the skin or subcutaneous tissue observed in late adverse events.

The Beijing trial involved 820 pT3-4pN2-3 post-mastectomy breast cancer patients. These patients were randomly assigned to receive post-mastectomy radiotherapy (PMRT) of the chest wall and nodal irradiation at 50 Gray in 25 fractions over 5 weeks. Other patients were randomly assigned to a 3-week hypofractionation regimen delivering 43.5 Gray in 15 fractions.

The main objective was to compare local control between the conventional dose and hypofractionation groups. After 5 years, there were no significant differences in locoregional relapse rates. Additionally, both acute and late toxicities were comparable between the groups. The hypofractionated radiotherapy group experienced less severe acute skin toxicity (3% versus 8%; p<0.001).

Meta-analysis studies found no statistically significant differences between the two treatment approaches. These analyses examined locoregional recurrence, disease-free survival, distant metastasis, and overall survival. There were also no significant differences in acute and late skin toxicity, acute lung toxicity, lymphedema, shoulder restriction, and late cardiac-related toxicity between HRT and CF.

Overall, acute and late side effects tended to be lower after HRT compared to conventional fractionation. These side effects include breast shrinkage, distortion, induration, and shoulder stiffness. One trial indicated slightly better cosmetic outcomes in the HRT group, while other studies found no difference in cosmetic outcomes.

Long-term results support the use of HRT as a preferred alternative to the traditional 2 Gray daily fraction. A 2022 systematic review encompassed breast cancer patients ranging from ductal carcinoma in situ (DCIS) to more advanced stages. These patients underwent various treatments and were randomly assigned to either HRT or CF. While there was no specific analysis for these subgroups, the evidence strongly suggests that moderately hypofractionated irradiation is beneficial for these patients.

For cases of DCIS, there is randomized evidence supporting the consideration of HRT as the standard, with endorsements from ESTRO and the NCCN Guidelines. Recent randomized findings from the DBCG HYPO Trial demonstrated this. The use of moderately hypofractionated breast irradiation in cases of node-negative breast cancer or DCIS did not lead to an elevated occurrence of breast induration compared to standard fractionated therapy.

Moreover, the impact on surrounding normal tissues was minimal, with similar or less frequent effects observed in the 40-Gray group. Furthermore, the risk of locoregional recurrence over the course of 9 years remained notably low.

At the 2023 ASTRO annual meeting, a study involving 385 women with stage 0-III breast cancer compared HRT to CF after mastectomy with implant-based breast reconstruction. The results showed similar recurrence rates and no link between fractionation type and chest wall toxicity. This finding highlights the viability of hypofractionation in post-mastectomy breast reconstruction scenarios.

Ultra-Hypofractionation for Breast Cancer

Ultra-hypofractionated WBI has emerged as a notable and viable treatment option for early-stage breast cancers. This approach has acquired considerable attention for its ability to provide comparable oncologic and toxicity outcomes. It also offers the added benefits of enhanced patient convenience and improved radiotherapy compliance because treatment is delivered over an even shorter time than with moderate HRT.

Ultra-hypofractionation in 28.5 Gray in five fractions (once-a-week) may be considered for selected patients over 50 years following breast-conserving surgery with early-stage, node-negative disease. This evidence emerged from the ten-year results of the tumor and side-effect endpoints reported in the FAST trial. The FAST trial showed no significant difference in normal tissue effects and disease outcomes.

The FAST-Forward trial, a randomized phase 3 non-inferiority study, explored an ultra-hypofractionated treatment regimen of 26 Gray or 27 Gray in five fractions delivered within a week. This trial enrolled patients with pT1-3, pN0-1, and M0 status after mastectomy or breast-conserving surgery.

After a median follow-up of almost 6 years, the results indicated that this accelerated treatment approach was non-inferior to the standard 40 Gray in 15 fractions over 3 weeks for ipsilateral breast tumor relapse. Additionally, the ultra-hypofractionated schedule of 26 Gray demonstrated comparable safety in terms of normal tissue effects (whereas 27 Gray was worse).

Data beyond 5 years regarding local relapse or toxicity are currently unavailable. However, the trend-line in survival may actually favor the hypofractionated regimen, while late toxicity could still manifest on longer follow-up. Some consensus guidelines recommend ultra-hypofractionation in select circumstances based on the data available to date.

Current Guidelines for Breast Cancer

In 2018, the ASTRO guidelines recommended two specific hypofractionation schemes for women with invasive breast cancer undergoing whole-breast irradiation. These recommendations apply irrespective of various tumor and patient characteristics. Age and factors like tumor grade, chemotherapy, hormone receptor status, and HER2 receptor were deemed irrelevant in deciding to offer HRT. HRT was also suggested as an alternative for patients with DCIS.

The guidelines emphasized minimizing breast tissue exposure above the prescription dose. However, they did not provide clear recommendations on HRT for regional lymph nodes and the chest wall. Nevertheless, a subsequent randomized trial indicated that HRT post-mastectomy is as effective and safe as conventional fractionation. HRT post-mastectomy includes regional lymph node and chest wall irradiation, with no significant difference in late complications.

The European Society for Radiotherapy and Oncology's advisory committee and the St. Gallen 2021 consensus both strongly advocate for the use of hypofractionated radiation therapy across a broad range of breast cancer scenarios. These scenarios include whole-breast and chest wall irradiation, as well as regional nodal irradiation (RNI). The recommendations apply regardless of age at breast cancer diagnosis. The recommendations apply regardless of pathological tumor stage, breast cancer biology, surgical margins status, and tumor bed boost. The recommendations apply regardless of breast size, invasive or pre-invasive ductal carcinoma in situ disease, oncoplastic breast-conserving surgery, and use of systemic therapy. These schedules remain highly endorsed for patients with breast reconstructions after mastectomy as well.

While ultra-hypofractionation, a regimen of 26 Gray in five fractions, is gaining interest, the St. Gallen Panel has not established it as a standard treatment yet. However, recent ESTRO guidelines have embraced this approach for whole-breast irradiation and chest wall irradiation, particularly without breast reconstruction, or within a clinical trial or registered cohort. That said, practitioners are urged to proceed with caution when applying ultra-hypofractionation to chest wall irradiation post-breast reconstruction and to nodal irradiation.

The HYPORT-Adjuvant trial, a phase III study, is currently comparing the effectiveness of two radiation treatments for high-risk patients. It is examining if a 3-week schedule of 40 Gray in 15 fractions is as good as a 1-week schedule of 26 Gray in 5 fractions, including regional radiotherapy for both. Initial findings show a higher rate of grade 2/3 radiation dermatitis in the 3-week schedule (11.1%) than in the 1-week schedule (2.9%). The trial is still in progress and continuing to recruit patients. The interim analysis indicates that ultra-hypofractionation is feasible for acute toxicity management, but it should be restricted to randomized trials or registered cohorts until findings from ongoing studies are available.

Evidence for Prostate Cancer Treatment

Based on the 2020 GLOBOCAN data, prostate cancer ranks as the second most prevalent cancer in men worldwide. The evidence supporting hypofractionation for prostate cancer has grown substantially, with multiple randomized trials demonstrating its effectiveness across different risk categories.

For low- and intermediate-risk prostate cancer, hypofractionation is more frequently utilized (57.5% and 54.5%, respectively) compared to high-risk prostate cancer (41.2%, p<0.001). This pattern reflects the accumulated evidence showing that moderate hypofractionation provides equivalent cancer control outcomes while offering convenience and resource savings.

The radiobiological rationale for hypofractionation in prostate cancer is particularly strong. Prostate cancer cells typically have a low alpha/beta ratio, meaning they are more sensitive to larger radiation doses per fraction. This biological characteristic makes prostate cancer an ideal candidate for hypofractionated treatment approaches.

Evidence for Lung Cancer Treatment

Lung cancer remains a leading cause of cancer death worldwide. The application of hypofractionated radiotherapy and stereotactic body radiation therapy (SBRT) in lung cancer has transformed treatment for many patients. This is particularly true for those with early-stage disease who may not be candidates for surgery.

SBRT delivers very high doses of radiation in a small number of fractions with extreme precision. This approach has become a standard treatment option for early-stage non-small cell lung cancer (NSCLC) in patients who cannot undergo surgery, offering excellent local control rates.

For patients with locally advanced lung cancer, hypofractionated regimens have also shown promise, particularly in settings where concurrent chemotherapy may not be feasible due to patient fitness or resource constraints.

Current Guidelines and Recommendations

Multiple professional organizations have developed guidelines for implementing hypofractionated radiotherapy across different cancer types. These guidelines reflect the accumulated evidence from randomized clinical trials and meta-analyses.

For breast cancer, both ASTRO and ESTRO guidelines support the use of moderate hypofractionation as the standard of care for most patients undergoing whole-breast irradiation. The St. Gallen consensus has extended these recommendations to include chest wall irradiation and regional nodal irradiation.

For prostate cancer, guidelines from major organizations support moderate hypofractionation as a standard treatment option across risk categories. Ultra-hypofractionation (SBRT) is increasingly recognized as an acceptable alternative for low- and intermediate-risk disease.

For lung cancer, SBRT is recommended as the preferred treatment for early-stage NSCLC in patients who are not surgical candidates. Hypofractionated regimens are also endorsed for specific clinical scenarios in locally advanced disease.

Clinical Implications for Patients

The adoption of hypofractionated radiotherapy has significant implications for patients, particularly those in resource-limited settings.

Shorter treatment duration: Patients complete their radiation treatment in fewer visits. For breast cancer, treatment that once took 5 to 6 weeks can now be completed in 3 weeks or even 1 week with ultra-hypofractionation. For prostate cancer, treatment can be completed in 4 to 5 weeks with moderate hypofractionation or 1 to 2 weeks with SBRT.

Reduced travel and accommodation costs: Fewer treatment visits mean lower transportation costs and less time away from home and work. This benefit is particularly important for patients who must travel long distances to reach a radiotherapy center.

Increased access to treatment: By using each radiotherapy machine more efficiently, centers can treat more patients. This efficiency helps address the critical shortage of radiotherapy services in LMICs.

Comparable outcomes: The evidence from multiple randomized trials shows that hypofractionated regimens provide cancer control and survival outcomes that are at least as good as conventional fractionation. In some cases, side effects are actually less frequent with hypofractionation.

Similar or improved side effect profiles: Studies have generally found that acute and late side effects are comparable or lower with hypofractionation compared to conventional fractionation. For breast cancer, some trials showed better cosmetic outcomes with hypofractionation.

Limitations and Considerations

While the evidence supporting hypofractionation is strong, several important limitations and considerations must be acknowledged.

Technology requirements: Safe implementation of hypofractionation, particularly ultra-hypofractionation and SBRT, requires advanced technology and rigorous quality assurance. Centers without adequate equipment or trained personnel may not be able to safely deliver these treatments.

Training and expertise: The successful implementation of hypofractionation requires well-trained radiation oncologists, medical physicists, and radiation therapists. Ongoing training and certification are essential.

Limited long-term data for ultra-hypofractionation: While moderate hypofractionation has extensive long-term follow-up data, ultra-hypofractionation has less mature data, particularly beyond 5 to 10 years. Longer follow-up is needed to fully assess late toxicity and long-term cancer control.

Patient selection: Not all patients are appropriate candidates for ultra-hypofractionation. Factors such as tumor stage, nodal involvement, and prior treatments must be carefully considered.

Limited prospective data from LMICs: The review found that while there are non-prospective studies from LMICs that offer some insights, there were no prospective single-arm studies or clinical trials from LMICs that significantly enhanced the context and technological considerations beyond existing references.

Practical Recommendations

Based on the comprehensive evidence review, the authors provide the following recommendations for implementing hypofractionated radiotherapy:

1. Establish minimum infrastructure: Ensure access to a linear accelerator capable of 3D conformal radiation therapy, CT simulation with sub-3mm slice reconstruction, treatment planning software, immobilization devices, and a comprehensive quality assurance protocol.
2. Invest in training: Develop comprehensive training programs for radiation oncologists, medical physicists, and radiation therapists. Ensure staff certification and provide ongoing education.
3. Implement rigorous quality assurance: Perform quality assurance tasks more frequently than standard guidelines require. Conduct daily validation of image-to-accelerator alignment and regular end-to-end tests.
4. Follow established guidelines: Adhere to guidelines from ASTRO, ESTRO, and other professional organizations when selecting patients and designing treatment plans.
5. Start with moderate hypofractionation: For centers new to hypofractionation, begin with moderate hypofractionation regimens that have the most extensive evidence base before advancing to ultra-hypofractionation.
6. Use appropriate technology: For breast cancer, 2D techniques may be acceptable in selected cases where surrounding normal tissue allows. For prostate and lung cancer, use a minimum of 3D technology.
7. Participate in clinical trials: Where possible, enroll patients in clinical trials or registered cohorts, particularly for ultra-hypofractionation approaches where long-term data are still emerging.
8. Foster collaboration: Establish partnerships between centers in LMICs and experienced institutions in high-income countries to facilitate training, quality assurance, and knowledge exchange.

The global cancer burden continues to rise, and the shortage of radiotherapy services in LMICs represents a critical barrier to effective cancer care. Hypofractionated radiotherapy offers a practical solution that can help address this challenge while maintaining high-quality treatment outcomes.

The evidence presented in this review demonstrates that hypofractionation is not a compromise but rather a preferred approach for many clinical scenarios. With proper implementation, including adequate technology, trained personnel, and rigorous quality assurance, hypofractionated radiotherapy can significantly improve access to cancer care in resource-limited settings.

Frequently Asked Questions

What is hypofractionated radiotherapy?

Hypofractionated radiotherapy gives a higher radiation dose at each session, called a fraction. Moderate hypofractionation uses more than 2 to 4 Gray per fraction, and ultra-hypofractionation uses more than 5 Gray per fraction. This shortens the overall treatment course from weeks to days, while aiming to control the tumour as effectively as conventional radiotherapy.

How long does hypofractionated radiotherapy take compared with standard treatment?

For breast cancer, treatment that once took 5 to 6 weeks can now be completed in 3 weeks, or even 1 week with ultra-hypofractionation. For prostate cancer, moderate hypofractionation takes 4 to 5 weeks, or 1 to 2 weeks with stereotactic body radiation therapy. Fewer visits mean less travel and time away from home and work.

Is hypofractionated radiotherapy as effective as conventional radiotherapy?

Evidence from multiple randomised trials shows that hypofractionated schedules provide cancer control and survival outcomes at least as good as conventional fractionation for breast, prostate and lung cancers. In some trials, side effects were actually less frequent with hypofractionation. Long-term follow-up is more limited for ultra-hypofractionation than for moderate hypofractionation.

What side effects might I expect from hypofractionated radiotherapy?

Studies generally found acute and late side effects comparable to or lower than conventional fractionation. For breast cancer, some trials showed better cosmetic outcomes with hypofractionation. Reported effects include skin reactions, breast shrinkage or induration, and shoulder stiffness. In one post-mastectomy trial, severe acute skin toxicity was 3% with hypofractionation versus 8% with conventional treatment.

Who may be suitable for ultra-hypofractionated breast radiotherapy?

Ultra-hypofractionation of 28.5 Gray in five once-weekly fractions may be considered for selected patients over 50 years after breast-conserving surgery with early-stage, node-negative disease. A regimen of 26 Gray in five fractions within a week was non-inferior to 40 Gray in 15 fractions in a randomised trial. Longer-term data beyond five years are still unavailable.

What technology and safety checks are needed for hypofractionated radiotherapy?

Minimum requirements include a linear accelerator for 3D conformal radiotherapy, CT simulation with sub-3mm slice reconstruction, treatment planning software, immobilisation devices, a quality assurance protocol, and trained staff. For prostate and lung cancer, at least 3D technology is recommended. Quality assurance tasks should be performed more frequently than standard guidelines require, with daily checks of image-to-accelerator alignment.

Can hypofractionated radiotherapy be used for lung cancer?

Stereotactic body radiation therapy, a form of ultra-hypofractionation, is a standard treatment option for early-stage non-small cell lung cancer in patients who cannot undergo surgery, offering excellent local control. For locally advanced lung cancer, hypofractionated regimens have shown promise where concurrent chemotherapy may not be feasible due to patient fitness or resource constraints.

I have early-stage breast cancer and my doctor recommends 5 to 6 weeks of daily radiation. Should I get a second opinion about a shorter radiation schedule?

Yes, this is a reasonable question to raise. Moderate hypofractionation for whole-breast irradiation yields local control and survival outcomes at least as effective as conventional fractionation, and it is the standard regimen for most women after breast-conserving surgery or mastectomy. Treatment that once took 5 to 6 weeks can be completed in 3 weeks, or 1 week with ultra-hypofractionation for selected early-stage, node-negative patients over 50. A second opinion can confirm whether a shorter schedule fits your tumor and nodal status. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original Article Title: Optimizing Clinical Implementation of Hypofractionation: Comprehensive Evidence Synthesis and Practical Guidelines for Low- and Middle-Income Settings.

Journal: Cancers

License: CC BY (open access)

Authors: Starling MTM, Thibodeau S, de Sousa CFPM, Restini FCF, Viani GA, Gouveia AG, Mendez LC, Marta GN, Moraes FY.

Publication: Cancers, 2024, Volume 16, Article 539

DOI: https://doi.org/10.3390/cancers16030539

Publication Date: January 26, 2024

Author Affiliations: Division of Radiation Oncology, London Health Sciences Centre, London, Ontario, Canada; Division of Radiation Oncology, Kingston General Hospital, Queen's University, Kingston, Ontario, Canada; Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA; Radiation Oncology Department, Hospital Sirio Libanês, São Paulo, Brazil; Department of Medical Imagings, Ribeirão Preto Medical School, University of São Paulo, Brazil; Latin America Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; Division of Radiation Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada

This patient-friendly article is based on peer-reviewed research published in the journal Cancers. The original article is an open-access publication distributed under the terms of the Creative Commons Attribution (CC BY) license.